SA 103
Alternative Names: SA-103Latest Information Update: 03 Jun 2025
At a glance
- Originator Sian Wuhan Medical Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical B-cell lymphoma; Multiple myeloma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
Most Recent Events
- 01 Apr 2025 Preclinical trials in B-cell lymphoma in China (Parenteral), prior to April 2025 (Sian Wuhan Medical Technology pipeline, April 2025)
- 01 Apr 2025 Preclinical trials in Multiple myeloma in China (Parenteral), prior to April 2025 (Sian Wuhan Medical Technology pipeline, April 2025)
- 01 Apr 2025 Preclinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma in China (Parenteral), prior to April 2025 (Sian Wuhan Medical Technology pipeline, April 2025)